Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

$930.67

Updated: 05/11/2026, 03:55:51

Market Cap
$95.80B
Sector
Healthcare
Industry
Biotechnology
Country
US

No historical data available

Company Profile

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

USD
NASDAQ
CEO: Leonard S. Schleifer
Employees: 15,410
https://www.regeneron.com
Asset Summaries
Latest generated summaries for REGN

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
REGN-10-k-fy2025.html3.0 MBtext/htmlENFiled 04/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 49 KPI observations

Revenue

$14.3B

FY 2025 · Reported

Net income

$4.5B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

N/A

FY — · Reported

R&D intensity

40.8%

FY 2025 · Calculated

Share repurchases

$3.4B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Approved product portfolio with territories
Key commercial products: EYLEA HD and Dupixent

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Fully integrated biotechnology company

Fully integrated biotechnology company with one operating segment

100%
Source evidence
“Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.”

Fully integrated biotechnology company

Fully integrated biotech with ~45 product candidates in clinical development, most homegrown

98%
Source evidence
“Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.”

One operating segment

Single segment

100%
Source evidence
“We manage our business as one segment which includes all activities related to the discovery, development, and commercialization of medicines for serious diseases.”

Approved product portfolio with territories

15 approved products including EYLEA HD/EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Ordspono, Lynozyfic, Inmazeb, Veopoz, ARCALYST, ZALTRAP

100%
Source evidence
“Products that have received marketing approval are summarized in the table below.”

Key commercial products: EYLEA HD and Dupixent

Profitability depends significantly on commercializing EYLEA HD and Dupixent

97%
Source evidence
“Our ability to generate profits and to generate positive cash flow from operations over the next several years depends significantly on the success in commercializing our products, including EYLEA HD and Dupixent.”

Net product sales of Regeneron-discovered products by product, 2023-2025

Dupixent global sales $17,806.7M (2025); total EYLEA HD + EYLEA $7,891.0M; Libtayo $1,452.2M; Praluent $856.8M

100%
Source evidence
“Dupixent(b) $13,187.0 $4,619.7 $17,806.7 $10,398.7 $3,749.3 $14,148.0 $8,855.6 $2,732.5 $11,588.1”

Operations and dependencies

Biological-source raw materials

Raw materials derived from biological sources including mammalian tissues, bovine serum, and human serum albumin, subject to regulatory restrictions

94%
Source evidence
“Certain of the raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin.”

Manufacturing facilities in Rensselaer, NY and Limerick, Ireland

Bulk drug materials manufactured at company-owned facilities in Rensselaer, New York and Limerick, Ireland, plus collaborators' and contract manufacturers' facilities

98%
Source evidence
“Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, as well as at our collaborators' and contract manufacturers' facilities.”

Reliance on collaborators/suppliers for manufacturing and distribution steps

Dependent on collaborators (Sanofi, Bayer, Ultragenyx, Kiniksa) and suppliers for manufacturing and distribution

100%
Source evidence
“the ability of our collaborators, suppliers, or other parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates”

Single-source suppliers for certain raw materials

Certain raw materials, some difficult to source, provided by single-source unaffiliated third-party suppliers

97%
Source evidence
“Certain raw materials or other products necessary for the manufacture and formulation of our marketed products and product candidates, some of which are difficult to source, are provided by single-source unaffiliated third-party suppliers.”

China-based supplier dependency and BIOSECURE Act risk

Company and third parties depend on China-based suppliers for certain raw materials, products, services, and preclinical/clinical development activities; could be restricted by US-China tensions, tariffs, or the BIOSECURE Act

95%
Source evidence
“depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities ... could be restricted due to geopolitical developments between the United States and China, including as a result of the escalation of tariffs or other trade restrictions or the recently enacted BIOSECURE Act”

Workforce profile as of December 31, 2025

15,410 full-time employees (11,961 US, 2,149 Ireland, 1,300 other); 6,717 in industrial operations and product supply

100%
Source evidence
“As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries”

Hiring and training needs for manufacturing expansion

Will need to hire and train significant numbers of employees and managerial personnel to staff expanding manufacturing and supply chain operations and future fill/finish activities

90%
Source evidence
“we will need to hire and train significant numbers of employees and managerial personnel to staff our expanding manufacturing and supply chain operations, as well as any future fill/finish activities”

Positioning and strategy

Fill/finish facility under construction in Rensselaer, NY

Constructed a fill/finish facility in Rensselaer, New York, currently undergoing process validation and not yet approved for commercial production

95%
Source evidence
“we have constructed a fill/finish facility in Rensselaer, New York that is currently undergoing process validation and has yet to be approved for commercial production”

Libtayo PD-1/PD-L1 competition

Libtayo competes with PD-1/PD-L1 antibodies including Keytruda, Opdivo, Tecentriq, Imfinzi, and Unloxcyt, some approved or in development for subcutaneous use.

95%
Source evidence
“including Merck's Keytruda® (pembrolizumab), Bristol-Myers Squibb's Opdivo® (nivolumab), Roche's Tecentriq® (atezolizumab), AstraZeneca's Imfinzi® (durvalumab), and Sun Pharma's Unloxcyt™ (cosibelimab)”

Lynozyfic competition in multiple myeloma

Lynozyfic faces competition from bispecific antibodies and CAR-T therapies targeting BCMA and GPRC5D in relapsed/refractory multiple myeloma.

90%
Source evidence
“Lynozyfic faces significant actual and potential future competition from other bispecific antibodies and CAR-T cell therapies targeting BCMA, GPRC5D, and/or other targets”

Dupixent competitive landscape

Dupixent faces competition from JAK inhibitors, antibodies against IL-13, IL-4Ra, IL-31R, OX40(L), IL-5, IgE, TSLP, IL-33, a BTK inhibitor in CSU, and inhaled products.

90%
Source evidence
“There are systemic JAK inhibitors and antibodies against IL-13 and IL-4Ra approved or in development for atopic dermatitis.”

Sanofi and Bayer collaboration profits drive results

Quarterly results depend on collaborations with Sanofi and Bayer, including collaboration profit share and R&D reimbursement

95%
Source evidence
“the continuation of our collaborations, in particular with Sanofi and Bayer, including our share of collaboration profits from sales of commercialized products and the amount of reimbursement of our research and development expenses that we receive from collaborators”

Manufacturing capabilities for non-core modalities

May need to develop or acquire additional manufacturing capabilities for drugs generated by technologies other than Trap or VelociSuite, such as siRNA, genome editing, and viral-based gene delivery

90%
Source evidence
“we may need to develop or acquire additional manufacturing capabilities as we and/or our collaborators continue to pursue the development of drugs generated by means other than our established "Trap" or VelociSuite technologies, such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression”

Core business strategy based on proprietary technologies and human genetics

Science- and genetics-driven integrated multi-product strategy

100%
Source evidence
“Our core business strategy is to maintain a strong foundation in scientific research and drug development using our proprietary technologies, and to build on that foundation with our clinical development, manufacturing, and commercial capabilities.”

Risks, financing, and outlook

Expanding unreimbursed R&D and commercialization costs

Substantial unreimbursed R&D and commercialization expenses expected to continue

93%
Source evidence
“our research and development activities and related costs which are not reimbursed by collaborators are expected to expand and require additional resources”

Risk of collaboration cancellation or termination

Sanofi and Bayer collaboration termination flagged as forward-looking risk

100%
Source evidence
“the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated”

Healthcare fraud, transparency, anti-bribery, and data privacy regulation exposure

Subject to anti-kickback/false claims laws, FCPA, HIPAA, FTC privacy rules, GDPR, and environmental statutes

100%
Source evidence
“Such laws include the EU's General Data Protection Regulations ("GDPR"), which has a wide range of compliance obligations relating to the processing and protection of personal data.”

Reimbursement and drug pricing risk

Dependence on third-party payor reimbursement (Medicare/Medicaid, PBMs) and drug pricing regulation changes

100%
Source evidence
“the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid”

Litigation and IP litigation risk

Litigation, government investigations, and patent litigation risk (Note 16)

100%
Source evidence
“risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report)”

Tariffs and trade restrictions risk

Tariffs and trade restrictions risk to manufacturing and supply chains

100%
Source evidence
“our ability to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions”

Substantial dependence on EYLEA HD, EYLEA, and Dupixent

We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent.

98%
Source evidence
“We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent.”

Excess inventory/capacity risk; REGEN-COV inventory write-downs

Recorded substantial inventory write-down charges related to REGEN-COV in each of 2022 and 2021 due to underperformance/discontinuation

96%
Source evidence
“during each of the years ended December 31, 2022 and 2021, we recorded a substantial charge to write down inventory related to REGEN-COV®.”

Bayer collaboration dependency and termination rights

Regeneron relies on Bayer (and Santen in Japan) for EYLEA HD/EYLEA sales outside the U.S.; Bayer may terminate on six or twelve months' notice.

95%
Source evidence
“Under the terms of our license and collaboration agreement with Bayer (which is terminable by Bayer at any time upon six or twelve months' advance notice, depending on the circumstances giving rise to termination)”

EYLEA U.S. sales decline and biosimilar competition

EYLEA U.S. net product sales declined 42% in 2025; FDA-approved biosimilars launched with more expected in H2 2026 following May 2024 U.S. exclusivity expiration.

95%
Source evidence
“For the year ended December 31, 2025, EYLEA U.S. net product sales declined by 42% compared to the corresponding period in 2024 as a result of competitive pressures”

Sanofi co-commercialization dependency and litigation

Regeneron relies on Sanofi for Dupixent sales/marketing including U.S. product sales recording and payor negotiations; Regeneron sued Sanofi (Antibody Collaboration Litigation) over information access and audit rights.

95%
Source evidence
“we have sued Sanofi and certain of its affiliated entities (the "Antibody Collaboration Litigation") alleging that the defendants breached certain provisions of the agreement governing the Antibody Collaboration”

Limited manufacturing capacity and facility concentration

Reliance on limited internal and contracted manufacturing; failures at Rensselaer, NY and Limerick, Ireland facilities would impair product supply.

95%
Source evidence
“failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland, or failures at the facilities of any other party participating in the supply chain would adversely affect our ability to supply our products.”

cGMP compliance and FDA inspection risk at manufacturing sites

Multiple products produced at Rensselaer and Limerick increases cGMP compliance risk; FDA has issued CRLs to multiple companies (including Regeneron) citing unresolved inspection findings at third-party manufacturers

93%
Source evidence
“Because we produce multiple products and product candidates at our facilities in Rensselaer, New York and Limerick, Ireland, there are increased risks associated with cGMP compliance.”

Regulatory approval and commercialization uncertainty

Uncertainty over regulatory approvals and successful commercialization/profitability of new products

92%
Source evidence
“There is uncertainty surrounding whether or when new products or new indications for marketed products will receive regulatory approval”

Natural gas and supply chain interruption exposure

Manufacturing could halt due to supply chain interruptions including natural gas and raw materials, business interruptions, labor shortages, war, or disasters

92%
Source evidence
“supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism”

Biologics manufacturing complexity and patent infringement risk in supply chain

Biologics require more difficult processing steps than chemical pharmaceuticals; manufacturing activities and supply chain depend on avoiding infringement of third-party patents

90%
Source evidence
“As our products and most of our product candidates are biologics, they require processing steps that are more difficult than those required for many other chemical pharmaceuticals.”

Tariffs and trade restrictions risk

Company faces risks from tariffs and other trade restrictions which may materially adversely impact results

90%
Source evidence
“We face risks associated with tariffs and other trade restrictions, which may have a material adverse impact on our results of operations and financial condition”

Pricing and reimbursement risk

Product sales depend on third-party coverage/reimbursement and copay assistance; drug price control measures in the U.S. could change pricing.

90%
Source evidence
“dependent on the availability and extent of coverage and reimbursement or copay assistance from third-party payors and other third parties, including private payors and government programs such as Medicare and Medicaid”

Parallel importation/reimportation pricing risk

U.S. sales may be reduced by imports from lower-priced markets (Canada, Mexico); an April 2025 executive order directed HHS to facilitate importation at the state level.

90%
Source evidence
“an executive order from April 2025 directed the Secretary of the HHS to take appropriate steps to facilitate such importation at the state level”

Healthcare law compliance and litigation exposure

Exposure to product liability, healthcare fraud/abuse laws, Medicaid rebate compliance, FCPA/U.K. Bribery Act, and environmental regulations.

90%
Source evidence
“If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines.”

Excess inventory and unused capacity risk

If product sales miss expectations or launches are delayed, Regeneron may face costs from excess inventory or unused capacity at its own and third-party facilities.

90%
Source evidence
“we may face costs related to excess inventory or unused capacity at our manufacturing facilities and at the facilities of third parties or our collaborators.”

Geopolitical exposure: Russia-Ukraine conflict

Third-party supply failures could result from geopolitical developments such as the armed conflict between Russia and Ukraine

88%
Source evidence
“labor shortages or disputes (in each case, including as a result of public health outbreaks, epidemics, or pandemics or other geopolitical developments, such as the armed conflict between Russia and Ukraine)”

ZALTRAP off-label compounding risk

Third parties may repackage ZALTRAP for off-label use in eye diseases, where it has not been formulated for intravitreal injection.

85%
Source evidence
“third parties repackage ZALTRAP for off-label use and sale for the treatment of diseases of the eye, even though ZALTRAP has not been manufactured and formulated for use in intravitreal injections”

Material exposure graph

EYLEA HD / EYLEA
Revenue Exposure

31% of 2025 total revenues from U.S. EYLEA HD/EYLEA net sales; EYLEA U.S. sales fell 42% on competitive/biosimilar pressure with more biosimilars expected in H2 2026.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31% and 42% of our total revenues, respectively.”
EYLEA HD and Dupixent
Demand Driver

Profitability and positive operating cash flow depend significantly on successful commercialization of EYLEA HD and Dupixent.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“depends significantly on the success in commercializing our products, including EYLEA HD and Dupixent”
Sanofi
Revenue Exposure

Dupixent, the largest Regeneron-discovered product with $17,806.7M global sales in 2025, is commercialized in collaboration with Sanofi; Regeneron records profit share/royalties and has supply obligations.

Relevance 95·Dependency 80·Confidence 100
Source evidence
“(b) In collaboration with Sanofi”
Sanofi
Revenue Exposure

Sanofi collaboration, including profit share from commercialized products and R&D reimbursement, materially drives Regeneron's financial results.

Relevance 90·Dependency 85·Confidence 93
Source evidence
“the continuation of our collaborations, in particular with Sanofi and Bayer”
Dupixent
Revenue Exposure

Dupixent is one of three products on which Regeneron is substantially dependent; Sanofi records U.S. sales and leads payor negotiations, creating reliance.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“We are substantially dependent on the success of EYLEA HD, EYLEA, and Dupixent.”
Bayer
Supplier Dependency

Bayer handles EYLEA HD/EYLEA commercialization outside the U.S.; termination on six or twelve months' notice would materially harm ex-U.S. revenue.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“we rely on Bayer (and, in Japan, Santen pursuant to a Co-Promotion and Distribution Agreement with Bayer's Japanese affiliate) for sales, marketing, and distribution of EYLEA HD and EYLEA outside the United States.”
Sanofi
Supplier Dependency

Sanofi records Dupixent U.S. sales, leads payor negotiations, and handles ex-U.S. commercialization; ongoing Antibody Collaboration Litigation adds relationship risk.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“Sanofi records product sales for Dupixent in the United States and leads negotiations with payors relating to this product.”
EYLEA biosimilars
Competitive Exposure

Post-May 2024 U.S. exclusivity expiration, FDA-approved EYLEA biosimilars (one launched; more expected H2 2026) will likely further reduce EYLEA/EYLEA HD sales and Bayer collaboration revenue ex-U.S.

Relevance 90·Dependency 85·Confidence 95
Source evidence
“including competition from additional biosimilar versions of EYLEA expected to launch in the United States in the second half of 2026, which may have a material adverse impact on our results of operations.”
Limerick, Ireland
Manufacturing Dependency

Limerick, Ireland is one of two company-owned bulk drug manufacturing sites; business interruption or regulatory action there would impair product supply.

Relevance 90·Dependency 75·Confidence 97
Source evidence
“Bulk drug materials are currently manufactured at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
Rensselaer, New York
Manufacturing Dependency

Rensselaer, NY is a primary bulk drug manufacturing site and houses a fill/finish facility still undergoing process validation; concentration of production creates supply interruption risk.

Relevance 90·Dependency 75·Confidence 97
Source evidence
“the manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
U.S. drug pricing and reimbursement regulation
Regulatory Exposure

Sales depend on coverage/reimbursement by Medicare/Medicaid and private payors; drug price control measures could reduce pricing.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“drug price control measures that have been or may be enacted or introduced in the United States by various federal and state authorities”
Medicare and Medicaid reimbursement rules
Regulatory Exposure

Commercial success of Regeneron's products depends on reimbursement and copay assistance availability from Medicare, Medicaid, PBMs, and private payors.

Relevance 85·Dependency 70·Confidence 100
Source evidence
“coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties”
China
Supplier Dependency

Regeneron and its collaborators/third parties depend on China-based suppliers for certain raw materials, products, services, and preclinical/clinical development activities; US-China tensions, tariffs, and the BIOSECURE Act could restrict this access.

Relevance 85·Dependency 60·Confidence 93
Source evidence
“depend on China-based suppliers or service providers for certain raw materials, products and services, or other activities”
Limerick, Ireland
Manufacturing Dependency

Failures at Limerick, Ireland (or Rensselaer, NY) facilities would adversely affect ability to supply products.

Relevance 80·Dependency 75·Confidence 95
Source evidence
“failures at our manufacturing facilities in Rensselaer, New York and Limerick, Ireland”
Regulatory approval
Regulatory Exposure

Pipeline value depends on uncertain regulatory approvals of new products and indications.

Relevance 80·Dependency 70·Confidence 90
Source evidence
“whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such products”
Bayer
Revenue Exposure

Bayer collaboration profit share and R&D reimbursement drive quarterly results.

Relevance 75·Dependency 60·Confidence 93
Source evidence
“the continuation of our collaborations, in particular with Sanofi and Bayer”
Bayer
Revenue Exposure

Aflibercept (EYLEA/EYLEA HD) outside the United States is in collaboration with Bayer, covering $3,506.3M of ex-U.S. EYLEA franchise sales in 2025.

Relevance 70·Dependency 60·Confidence 100
Source evidence
“(a) In collaboration with Bayer outside the United States.”
BIOSECURE Act
Regulatory Exposure

The recently enacted BIOSECURE Act, together with tariffs and trade restrictions, could restrict engagement of China-based suppliers or service providers for preclinical and clinical development programs.

Relevance 70·Dependency 50·Confidence 92
Source evidence
“the escalation of tariffs or other trade restrictions or the recently enacted BIOSECURE Act”
healthcare fraud and abuse laws
Legal Exposure

Business activities have been and may be challenged under U.S. federal or state and foreign healthcare laws, subjecting the company to civil or criminal proceedings, investigations, or penalties.

Relevance 65·Dependency 50·Confidence 90
Source evidence
“Our business activities have been, and may in the future be, challenged under U.S. federal or state and foreign healthcare laws, which may subject us to civil or criminal proceedings, investigations, or penalties.”
natural gas
Cost Driver

Manufacturing continuity depends on availability of natural gas and other raw materials; supply chain interruptions or constraints including natural gas could halt production.

Relevance 60·Dependency 45·Confidence 90
Source evidence
“supply chain interruptions or constraints (including with respect to natural gas and other raw materials)”
tariffs and trade restrictions
Cost Driver

Tariffs and trade restrictions could impair Regeneron's ability to manufacture and manage supply chains for multiple products and candidates.

Relevance 60·Dependency 45·Confidence 100
Source evidence
“our ability to manufacture and manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions”
biological source raw materials
Raw Material Dependency

Products rely on biological-source raw materials (mammalian tissues, bovine serum, human serum albumin) subject to regulatory restrictions; forced substitution could delay development or commercial activities.

Relevance 55·Dependency 50·Confidence 92
Source evidence
“raw materials required in the manufacture and testing of our products and product candidates may be derived from biological sources, including mammalian tissues, bovine serum, and human serum albumin”
Ireland
Manufacturing Dependency

2,149 of 15,410 full-time employees are employed in Ireland, representing a significant portion of industrial operations and product supply capability.

Relevance 55·Dependency 45·Confidence 90
Source evidence
“2,149 employed in Ireland”
EU General Data Protection Regulation
Regulatory Exposure

GDPR compliance obligations carry significant financial penalties and a private right of action for data subjects.

Relevance 55·Dependency 45·Confidence 100
Source evidence
“Violations of the GDPR carry significant financial penalties for noncompliance.”
siRNA gene silencing and other non-core modalities
Technology Dependency

Pursuit of drugs based on siRNA gene silencing, genome editing, and targeted viral-based gene delivery requires developing or acquiring additional manufacturing capabilities beyond established Trap/VelociSuite technologies.

Relevance 55·Dependency 40·Confidence 88
Source evidence
“such as siRNA gene silencing, genome editing, and targeted viral-based gene delivery and expression”
Full company information
Latest profile, trading, valuation, and identifier data stored for REGN.
Share price
$930.67
Market cap
$95.80B
Exchange
NASDAQ
Currency
USD
CEO
Leonard S. Schleifer
Employees
15,410
IPO date
02/04/1991
Beta
0.236
Last dividend
$0.00
Day range
$927.45 – $991.73
52-week range
$591.52 – $991.73
1-day performance
-4.39%
1-year performance
57.34%
Current drawdown (1Y)
-6.16%
CIK
0000872589
CUSIP
75886F107
ISIN
US75886F1075
Created
07/12/2025, 13:57:16
Last update
05/11/2026, 03:55:51

Track Regeneron Pharmaceuticals, Inc. with an AI analyst

See which prediction-market events move REGN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to REGN from your Railway `news_articles` table.

Here's Why Regeneron (REGN) is a Strong Value Stock

Zacks Investment Research • STOCK • 12/06/2026, 12:41:12

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Business Wire • STOCK • 10/06/2026, 17:00:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

GlobeNewsWire • STOCK • 09/06/2026, 15:35:00

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • STOCK • 08/06/2026, 19:38:30

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

Seeking Alpha • STOCK • 08/06/2026, 04:48:49

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

Zacks Investment Research • STOCK • 04/06/2026, 16:25:14

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

GlobeNewsWire • STOCK • 02/06/2026, 18:32:00

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

Zacks Investment Research • STOCK • 01/06/2026, 13:35:11

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Zacks Investment Research • STOCK • 01/06/2026, 13:35:10

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

GlobeNewsWire • STOCK • 28/05/2026, 18:00:00

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

24/7 Wall Street • STOCK • 28/05/2026, 13:04:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

GlobeNewsWire • STOCK • 26/05/2026, 18:53:00